Clinical Trials
53 trialsPembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Dana-Farber Cancer Institute
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
University of Michigan Rogel Cancer Center
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)
Dizal Pharmaceuticals
Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine
The Lymphoma Academic Research Organisation
AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)
Dizal Pharmaceuticals
PRIMO
SecuraBio
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
Ohio State University Comprehensive Cancer Center
REDIRECT
Affimed GmbH
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
BeiGene
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
HUYABIO International, LLC.
AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL
AstraZeneca
PTCL
Kura Oncology, Inc.
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Kyowa Kirin Co., Ltd.
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Seagen Inc.
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Kyowa Kirin Co., Ltd.
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Solasia Pharma K.K.
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
University of Nebraska
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
University of Nebraska
CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Weill Medical College of Cornell University
Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
Eastern Cooperative Oncology Group
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
PTCL
Spectrum Pharmaceuticals, Inc
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
Eisai Inc.
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
National Cancer Institute (NCI)
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Eisai Inc.
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Celgene
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Allo-hNHL (FluBuCy)
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
PROPEL
Acrotech Biopharma Inc.
Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies
Acrotech Biopharma Inc.
FIL_GEMRO
Fondazione Italiana Linfomi - ETS
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
University of Chicago
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
M.D. Anderson Cancer Center
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Wake Forest University Health Sciences
Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma
Lymphoma Study Association
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
Fred Hutchinson Cancer Center
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
University of Washington
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Fred Hutchinson Cancer Center
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
Yale University
Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Singapore General Hospital
CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
University of Göttingen
PTCL-06
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
Alaunos Therapeutics